News

Newsletter

Brazilian National Health Surveillance Agency (ANVISA) decides not to comment on a bill that proposes changes to the Industrial Property Act

he  Last Tuesday (February 9th, 2021), the Board of the National Health Surveillance Agency (ANVISA) decided not to comment on the Senate Bill (PLS) 2,410 / 2020, which proposes amendments to Law 9,279 / 1996 (Brazilian Industrial Property Act) addressing fast-track examination of patent applications related to epidemics control.
 
Such bill establishes that Patent Applicants may reasonably request the Ministry of Health to prioritize the examination of patents related to products, processes, equipment and materials that the Ministry itself recognizes as essential for epidemics control.
 
As a matter of fact, fast-track of patent applications claiming technologies to fight Covid-19 has already been regulated by the National Institute of Industrial Property (INPI) by means of Ordinance No. 149/2020. In addition, INPI already carries out priority procedures for patent applications related to health products, of public interest or national emergency, according to Resolution 239/2019. However, Bill PLS 2,410 / 2020 would establish a new form of prioritization for epidemics in general.
 
In his opinion, ANVISA’s President Antônio Barra Torres stressed that the competence of ANVISA's Intellectual Property Coordination is limited to grant prior consent for patent applications claiming pharmaceutical products and processes – in accordance with article 229-C of the Brazilian Industrial Property Act – which is limited to the analysis of risk to public health.
 
Barra Torres also highlighted that INPI is the sole body with competence to establish the procedures for the analysis and granting of patents the INPI, and this matter falls out of the scope of ANVISA’s legal. Thus, he concluded that ANVISA should not issue an opinion on PLS 2.410 / 2020. The majority of the Board concurred with Barra Torres.
 
Still in 2020, former Director Alessandra Bastos Soares had issued an opinion stating that ANVISA should not oppose the bill, stating that establishing a fast-track procedure of patent applications by the very Ministry of Health could strengthen ANVISA's participation in issues related to the relationship between industrial property and public health.
 
PLS 2,410 / 2020 is yet to be voted by the Federal Senate.
 
Should you have any questions, our team is at your disposal at mail@kasznarleonardos.com.
Back

Last related news

November 22, 2021

Kasznar Leonardos receives ISO 9001 certification of quality

The ISO 9001 standard recognizes operational efficiency, focusing specifically on excellent customer service and continual process improvement. Our firm has received ISO Kasznar Leonardos receives ISO 9001 certification of quality

  • Kasznar Leonardos
  • Ler notícia

    November 12, 2021

    BPTO recognizes the Right of Precedence as an argument for filing Administrative Nullities

    By Flávia Tremura and Isabella Faccioli From November 2021 the BPTO will start to accept the right of precedence of the trademark BPTO recognizes the Right of Precedence as an argument for filing Administrative Nullities

  • Kasznar Leonardos
  • Ler notícia

    September 3, 2021

    The Covid-19 pandemic triggered the issuance of new compulsory license rules for patents in Brazil

    On Sept. 2nd, 2021, Law No 14,200 was enacted to amend the Brazilian Patent & Trademark Act (BPTA) in order to change The Covid-19 pandemic triggered the issuance of new compulsory license rules for patents in Brazil

    Ler notícia